We retrospectively compared the antileukemic effects of chemotherapy alone and
chemotherapy followed by modified donor lymphocyte infusion (DLI) in 82 patients with …

Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML)
relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain …

Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed
acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation …

Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for
relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host …

Background Donor lymphocyte infusion (DLI) was used as salvage therapy in leukemia
relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), but existing …

Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell
transplantation (HSCT). In this retrospective study, 23 patients [15 (65.2%) AML, eight …

Patients with refractory/relapsed acute leukemia who have received allogeneic
hematopoietic stem cell transplantation (allo-HSCT) are still at a high risk for relapse post …

Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute
lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow …

We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in
complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT) …

This study investigated the prognostic factors in patients (n= 89) who experienced relapse
and received chemotherapy plus donor leukocyte infusion (Chemo-DLI) after haploidentical …